Global Clinical Diagnostics Outlook, 2024

Global Clinical Diagnostics Outlook, 2024

Driven by Digital Services and Automation, the Molecular Diagnostics and POCT Sectors Rebound after the COVID-19 Pandemic

RELEASE DATE
18-Apr-2024
REGION
Global
Deliverable Type
Market Outlook
Research Code: KA03-01-00-00-00
SKU: CM_2024_673
AvailableYesPDF Download
$4,950.00
In stock
SKU
CM_2024_673

Global Clinical Diagnostics Outlook, 2024
Published on: 18-Apr-2024 | SKU: CM_2024_673

Need more details?
$4,950.00
DownloadLink
Need more details?

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will likely witness sustained growth through to 2029. The main growth drivers will be the point-of-care testing (POCT) and molecular diagnostics sectors, which Frost & Sullivan expects to rebound even more strongly in 2024.

This study examines clinical diagnostics industry trends and growth projections from 2024 to 2029 across five global regions. It analyzes innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic reality. The research also provides the top 5 predictions for 2024 related to the industry’s decentralization trend, the recovery of molecular diagnostics, and the higher investments in automated solutions and novel digital models.

Analysis Highlights

The 2023 Clinical Diagnostics Industry: Forecast vs. Actual

Top Clinical Diagnostics Predictions for 2024

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Clinical Diagnostics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Segmentation

Growth Environment

Growth Environment (continued)

Top 10 Trends for 2024

Top 10 Growth Opportunities

1. Global GDP Growth—Mild Global Growth Slowdown from 3.0% in 2023 to 2.6% in 2024 as Key Economies Lose Growth Momentum

2. Inflation and Interest Rates—Headline Inflation to Continue to Decline; H2 2024 Shift Toward Rate Cuts for Advanced Economies

3. Currency Trajectory—Dollar to Remain Strong in H1 2024; Emerging Market Currencies to Get Boost from Q3 2024 Onwards

4. Labor Market—Moderate Unemployment Uptick; Positive Expectations Over Market Sentiment to Support Labor Hoarding

5. Oil Markets—Q1 OPEC+ Oil Production Cuts; Non-OPEC Production to Rise

6. Critical Minerals Supplies—Need for Economic Resiliency to Bolster Cross-border and Cross-industry Partnerships

7. North America—Economic Slowdown Amidst Discretionary Spending Pullback and Elevated Interest Rates

8. Western Europe—Moderate Growth Pick-up as Inflation Headwinds Ease Gradually; Rebuilding Fiscal Buffers to Take Precedence

9. Middle East—Non-oil Growth Driven by Economic Diversification to Limit Pullback Caused by a Slowdown in Global Oil Markets

10. Asia—Emerging Economies to Drive Growth Momentum; Fiscal Measures to Support Chinese Economic Recovery

Forecast Assumptions: Clinical Diagnostics Industry

Clinical Diagnostics Industry by Segment

Revenue Forecast by Subsegment

Revenue Forecast by Subsegment (continued)

Revenue Forecast by Segment: Centralized Testing

Revenue Forecast by Segment: Referral & Peripheral and Decentralized Testing

Revenue Forecast by Region

Revenue Forecast by Region (continued)

Percent Revenue Forecast by Region

Revenue Forecast Analysis by Region

Revenue Forecast Analysis by Region (continued)

Competitive Environment

Revenue Share

Revenue Share Analysis

Competitor Matrix

Competitor Matrix (continued)

Notable M&As in 2023

M&As: Historical Analytics

Prediction 1: Long-term Change in Consumer Behavior Supports Expansion into Self-collection Testing

Prediction 2: Staff Shortages Continue to Drive Double-digit Lab Automation Growth Rate

Prediction 3: Adoption of NGS and Specialized Bioinformatics Tools Will Support Pharma Innovation

Prediction 4: ctDNA Analysis Will Expand the Application of MRD Testing for Precision Oncology

Prediction 5: Partnerships with AI-focused Start-ups to Promote Adoption of AI-based Digital Pathology in Clinical Segments

2024 Industry Snapshot

Clinical Chemistry and Immunoassays Industry Snapshot

Clinical Chemistry and Immunoassays Industry: Companies to Watch

Molecular Diagnostics Industry Snapshot

Molecular Diagnostics Industry: Companies to Watch

POCT Industry Snapshot

POCT Industry: Companies to Watch

Tissue Diagnostics Industry Snapshot

Tissue Diagnostics Industry: Companies to Watch

Growth Opportunity 1: Shift toward Digital Diagnostics Services

Growth Opportunity 1: Shift toward Digital Diagnostics Services (continued)

Growth Opportunity 2: Expansion of Clinical Chemistry and Immunoassays to Emerging Markets

Growth Opportunity 2: Expansion of Clinical Chemistry and Immunoassays to Emerging Markets (continued)

Growth Opportunity 3: Predictive Testing in Molecular Diagnostics for Genetics and Cardiovascular Diseases

Growth Opportunity 3: Predictive Testing in Molecular Diagnostics for Genetics and Cardiovascular Diseases (continued)

Growth Opportunity 4: Molecular POCT in Clinical Settings

Growth Opportunity 4: Molecular POCT in Clinical Settings (continued)

Growth Opportunity 5: Multiplex POCT for Immunoassay, STI, and AMR Applications

Growth Opportunity 5: Multiplex POCT for Immunoassay, STI, and AMR Applications (continued)

Conclusions and Future Outlook

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will likely witness sustained growth through to 2029. The main growth drivers will be the point-of-care testing (POCT) and molecular diagnostics sectors, which Frost & Sullivan expects to rebound even more strongly in 2024. This study examines clinical diagnostics industry trends and growth projections from 2024 to 2029 across five global regions. It analyzes innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic reality. The research also provides the top 5 predictions for 2024 related to the industry s decentralization trend, the recovery of molecular diagnostics, and the higher investments in automated solutions and novel digital models.
More Information
Deliverable Type Market Outlook
Author Lucila Martin
Industries Chemicals and Materials
No Index No
Is Prebook No
Podcast No
WIP Number KA03-01-00-00-00